Jennifer A. Johnston
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jennifer A. Johnston has a total of 204 co-authors. Here are the top co-authors by number of shared publications:
- Glenda Margaret Halliday
The University of Sydney
5 shared publications - Carolyn M. Sue
Aligning Science Across Parkinson's (ASAP) Collaborative Research Network Chevy Chase Maryland USA
4 shared publications - Clare L. Parish
Aligning Science Across Parkinson's (ASAP) Collaborative Research Network Chevy Chase Maryland USA
4 shared publications - Deniz Kirik
Brain Repair and Imaging in Neural Systems (B.R.A.I.N.S) Unit, Department of Experimental Medical Science, Lund University, BMC D11, 22184 Lund, Sweden
4 shared publications - Lachlan H. Thompson
School of Medical Sciences, University of Sydney, Sydney, NSW, Australia
4 shared publications J. William Langston
The Parkinson's Institute, Sunnyvale, California, United States of America
3 shared publications
Latest Publications
- Open Access
- 17 August 2026
- Published by Wiley in Neuropathology and Applied Neurobiology
- Vol. 52 (4) , e70097
Transgenic A53T Mice Have Astrocytic α‐Synuclein Aggregates in Dopamine and Striatal Regions
Aims: The accumulation of α‐synuclein in astrocytes in Parkinson's disease is considered to be secondary to neuronal accumulation. The aim of this study to identify whether astrocytes accumulate small α‐synuclein aggregates before or after neurons in the nigrostriatal pathway. Methods: Fixed serial midbrain and striatal sections from M83 A53T transgenic mouse model of Parkinson's disease and wild‐type controls were histologically processed for multiplex labelling of α‐synuclein and astrocytic markers and astrocyte quantitation performed on digital images using QuPath software. Results: The density of astrocytes within the substantia nigra pars compacta was approximately 30% greater compared with other sampled regions ( p < 0.005). Small aggregates of α‐synuclein were observed in astrocytic processes, including in wild‐type mice where a quarter of all astrocytes had an obvious α‐synuclein aggregate. Compared to wild‐type, A53T transgenic astrocytes had significantly enlarged somas ( p < 0.001) with more processes ( p < 0.001) consistent with a reactive phenotype. The A53T transgenic mice had more than double the numbers of astrocytes ( p < 0.001) and 2.5 times more astrocytes with α‐synuclein aggregates compared to wild‐type mice ( p < 0.001). Conclusions: These data suggest that small α‐synuclein aggregates are normally cleared by astrocytes and that the substantia nigra pars compacta requires more astrocytic support for this function than other midbrain dopaminergic regions or the striatum. This adds another vulnerability factor to those already known for the substantia nigra with early deficits in clearance of small α‐synuclein aggregates by astrocytes associated with increased astrocytic reactivity in the A53T transgenic mouse model.
- 17 August 2026
- Published by Wiley in Neuropathology and Applied Neurobiology
- Vol. 52 (4) , e70097
Open AccessTransgenic A53T Mice Have Astrocytic α‐Synuclein Aggregates in Dopamine and Striatal Regions
Aims: The accumulation of α‐synuclein in astrocytes in Parkinson's disease is considered to be secondary to neuronal accumulation. The aim of this study to identify whether astrocytes accumulate small α‐synuclein aggregates before or after neurons in the nigrostriatal pathway. Methods: Fixed serial midbrain and striatal sections from M83 A53T transgenic mouse model of Parkinson's disease and wild‐type controls were histologically processed for multiplex labelling of α‐synuclein and astrocytic markers and astrocyte quantitation performed on digital images using QuPath software. Results: The density of astrocytes within the substantia nigra pars compacta was approximately 30% greater compared with other sampled regions ( p < 0.005). Small aggregates of α‐synuclein were observed in astrocytic processes, including in wild‐type mice where a quarter of all astrocytes had an obvious α‐synuclein aggregate. Compared to wild‐type, A53T transgenic astrocytes had significantly enlarged somas ( p < 0.001) with more processes ( p < 0.001) consistent with a reactive phenotype. The A53T transgenic mice had more than double the numbers of astrocytes ( p < 0.001) and 2.5 times more astrocytes with α‐synuclein aggregates compared to wild‐type mice ( p < 0.001). Conclusions: These data suggest that small α‐synuclein aggregates are normally cleared by astrocytes and that the substantia nigra pars compacta requires more astrocytic support for this function than other midbrain dopaminergic regions or the striatum. This adds another vulnerability factor to those already known for the substantia nigra with early deficits in clearance of small α‐synuclein aggregates by astrocytes associated with increased astrocytic reactivity in the A53T transgenic mouse model.
- Open Access
- 1 August 2026
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 12 (1)
Machine learning image analysis predicts Parkinson disease genotype and mitochondrial lysosomal abnormalities in iPS neurons
Mitochondrial and lysosomal dysfunction are central features of Parkinson’s disease (PD) across major genetic forms including PRKN , SNCA , and LRRK2 . We applied cell morphomics , a machine-learning-based framework combining high-content imaging with quantitative feature extraction, to analyse mitochondrial and lysosomal morphology at single-cell resolution in iPS cell-derived cortical neurons from PD patients and healthy controls (13 lines total). Supervised machine-learning models distinguished PD neurons from controls with high accuracy (AUC = 0.87) and reliably separated individual genotypes. Feature importance and attribution analysis revealed genotype-specific organelle biases in the relative contribution of mitochondrial and lysosomal features, with mitochondrial features dominating classification in PRKN neurons, balanced mitochondrial and lysosomal contributions in SNCA neurons, and a greater lysosomal contribution in LRRK2 neurons. Multi-class models retained strong performance, and findings were reproduced across two independent laboratories using different dyes and imaging conditions. These results demonstrate that morphomics provides a robust and scalable framework to quantify genotype-specific organelle abnormalities in PD neurons and supports its application for cellular stratification and biomarker discovery.
- 1 August 2026
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 12 (1)
Open AccessMachine learning image analysis predicts Parkinson disease genotype and mitochondrial lysosomal abnormalities in iPS neurons
Mitochondrial and lysosomal dysfunction are central features of Parkinson’s disease (PD) across major genetic forms including PRKN , SNCA , and LRRK2 . We applied cell morphomics , a machine-learning-based framework combining high-content imaging with quantitative feature extraction, to analyse mitochondrial and lysosomal morphology at single-cell resolution in iPS cell-derived cortical neurons from PD patients and healthy controls (13 lines total). Supervised machine-learning models distinguished PD neurons from controls with high accuracy (AUC = 0.87) and reliably separated individual genotypes. Feature importance and attribution analysis revealed genotype-specific organelle biases in the relative contribution of mitochondrial and lysosomal features, with mitochondrial features dominating classification in PRKN neurons, balanced mitochondrial and lysosomal contributions in SNCA neurons, and a greater lysosomal contribution in LRRK2 neurons. Multi-class models retained strong performance, and findings were reproduced across two independent laboratories using different dyes and imaging conditions. These results demonstrate that morphomics provides a robust and scalable framework to quantify genotype-specific organelle abnormalities in PD neurons and supports its application for cellular stratification and biomarker discovery.
- Open Access
- 23 July 2026
- Published by Wiley in Biotechnology Progress
- p. e88542
High‐throughput development and scale‐up of recombinant adeno‐associated virus 5 anion‐exchange chromatography for high‐purity capsid separation
Recombinant adeno‐associated virus (rAAV) production commonly yields a high proportion of empty and partially filled capsids, necessitating downstream purification to enrich full capsids. Among purification approaches, anion‐exchange chromatography (AEX) has emerged as a scalable alternative to ultracentrifugation. In this study, a structured and scalable development strategy for AAV5 AEX purification is presented. A high‐throughput, ultra–scale‐down platform using 200 μL RoboColumns™ was established to enable rapid screening of salt systems, additives, and operating conditions with minimal material requirements. Dual‐salt systems were evaluated to decouple ionic strength from ion‐specific effects, leading to the identification of a magnesium‐only system (MgCl 2 /MgSO 4 ) that improved both enrichment and recovery. Optimized conditions achieved >85% full capsids with robust recovery and >90% full capsids in peak fractions. Scalability was demonstrated through strong agreement between ultra scale‐down (200 μL) and scale‐down (1 mL) formats. A QbD‐aligned framework was applied to define the purity–recovery design space and guide selection of operating conditions based on target product profile. The optimized gradient process was translated into a manufacturing‐relevant isocratic step format, with systematic evaluation of buffer conductivity sensitivity and load robustness to address large‐scale operational constraints.
- 23 July 2026
- Published by Wiley in Biotechnology Progress
- p. e88542
Open AccessHigh‐throughput development and scale‐up of recombinant adeno‐associated virus 5 anion‐exchange chromatography for high‐purity capsid separation
Recombinant adeno‐associated virus (rAAV) production commonly yields a high proportion of empty and partially filled capsids, necessitating downstream purification to enrich full capsids. Among purification approaches, anion‐exchange chromatography (AEX) has emerged as a scalable alternative to ultracentrifugation. In this study, a structured and scalable development strategy for AAV5 AEX purification is presented. A high‐throughput, ultra–scale‐down platform using 200 μL RoboColumns™ was established to enable rapid screening of salt systems, additives, and operating conditions with minimal material requirements. Dual‐salt systems were evaluated to decouple ionic strength from ion‐specific effects, leading to the identification of a magnesium‐only system (MgCl 2 /MgSO 4 ) that improved both enrichment and recovery. Optimized conditions achieved >85% full capsids with robust recovery and >90% full capsids in peak fractions. Scalability was demonstrated through strong agreement between ultra scale‐down (200 μL) and scale‐down (1 mL) formats. A QbD‐aligned framework was applied to define the purity–recovery design space and guide selection of operating conditions based on target product profile. The optimized gradient process was translated into a manufacturing‐relevant isocratic step format, with systematic evaluation of buffer conductivity sensitivity and load robustness to address large‐scale operational constraints.
- Open Access
- 29 August 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (35) , eady0240
Putative PINK1/Parkin activators lower the threshold for mitophagy by sensitizing cells to mitochondrial stress
The PINK1/Parkin pathway targets damaged mitochondria for degradation via mitophagy. Genetic evidence implicates impaired mitophagy in Parkinson’s disease, making its pharmacological enhancement a promising therapeutic strategy. Here, we characterize two mitophagy activators: a novel Parkin activator, FB231, and the reported PINK1 activator MTK458. Both compounds lower the threshold for mitochondrial toxins to induce PINK1/Parkin-mediated mitophagy. However, global proteomics revealed that FB231 and MTK458 independently induce mild mitochondrial stress, resulting in impaired mitochondrial function and activation of the integrated stress response, effects that result from PINK1/Parkin-independent off-target activities. We find that these compounds impair mitochondria by distinct mechanisms and synergistically decrease mitochondrial function and cell viability in combination with classical mitochondrial toxins. Our findings support a model whereby weak or “silent” mitochondrial toxins potentiate other mitochondrial stressors, enhancing PINK1/Parkin-mediated mitophagy. These insights highlight important considerations for therapeutic strategies targeting mitophagy activation in Parkinson’s disease.
- 29 August 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (35) , eady0240
Open AccessPutative PINK1/Parkin activators lower the threshold for mitophagy by sensitizing cells to mitochondrial stress
The PINK1/Parkin pathway targets damaged mitochondria for degradation via mitophagy. Genetic evidence implicates impaired mitophagy in Parkinson’s disease, making its pharmacological enhancement a promising therapeutic strategy. Here, we characterize two mitophagy activators: a novel Parkin activator, FB231, and the reported PINK1 activator MTK458. Both compounds lower the threshold for mitochondrial toxins to induce PINK1/Parkin-mediated mitophagy. However, global proteomics revealed that FB231 and MTK458 independently induce mild mitochondrial stress, resulting in impaired mitochondrial function and activation of the integrated stress response, effects that result from PINK1/Parkin-independent off-target activities. We find that these compounds impair mitochondria by distinct mechanisms and synergistically decrease mitochondrial function and cell viability in combination with classical mitochondrial toxins. Our findings support a model whereby weak or “silent” mitochondrial toxins potentiate other mitochondrial stressors, enhancing PINK1/Parkin-mediated mitophagy. These insights highlight important considerations for therapeutic strategies targeting mitophagy activation in Parkinson’s disease.
- Open Access
Transgenic A53T mice have astrocytic α-synuclein aggregates in dopamine and striatal regions
Aims: Parkinson’s disease is considered biologically a neuronal α-synuclein disease, largely ignoring the more widespread α-synuclein deposition that occurs in astrocytes, with the aim of this study to identify whether astrocytes accumulate small α-synuclein aggregates before or after neurons. Methods: Fixed serial midbrain and striatal sections from M83 A53T transgenic mouse model of Parkinson’s disease and wild-type controls were histologically processed for multiplex labelling of α-synuclein and astrocytic markers and astrocyte quantitation performed on digital images using QuPath software. Results: The density of astrocytes within the substantia nigra pars compacta was approximately 30% greater compared with other sampled regions ( P P P P P <0.001). Conclusions: These data suggest that small α-synuclein aggregates are normally cleared by astrocytes and that the substantia nigra pars compacta requires more astrocytic support for this function than other midbrain dopaminergic regions or the striatum. This adds another vulnerability factor to those already known for the substantia nigra with early deficits in clearance of small α-synuclein aggregates by astrocytes associated with an increased astrocytic reactivity in the A53T transgenic mouse model. Key Points: The substantia nigra pars compacta contains a higher density of astrocytes than the ventral tegmental area or striatum, indicating a greater reliance on astrocytic function and a greater vulnerability to astrocyte dysfunction Small aggregates of α-synuclein were observed in wild-type midbrain and striatal astrocytes, indicating normal clearance of α-synuclein by these astrocytes Midbrain and striatal astrocytes from A53T transgenic astrocytes have more than double the number of astrocytes and more astrocytes containing α-synuclein aggregates which have a reactive morphological phenotype.
Open AccessTransgenic A53T mice have astrocytic α-synuclein aggregates in dopamine and striatal regions
Aims: Parkinson’s disease is considered biologically a neuronal α-synuclein disease, largely ignoring the more widespread α-synuclein deposition that occurs in astrocytes, with the aim of this study to identify whether astrocytes accumulate small α-synuclein aggregates before or after neurons. Methods: Fixed serial midbrain and striatal sections from M83 A53T transgenic mouse model of Parkinson’s disease and wild-type controls were histologically processed for multiplex labelling of α-synuclein and astrocytic markers and astrocyte quantitation performed on digital images using QuPath software. Results: The density of astrocytes within the substantia nigra pars compacta was approximately 30% greater compared with other sampled regions ( P P P P P <0.001). Conclusions: These data suggest that small α-synuclein aggregates are normally cleared by astrocytes and that the substantia nigra pars compacta requires more astrocytic support for this function than other midbrain dopaminergic regions or the striatum. This adds another vulnerability factor to those already known for the substantia nigra with early deficits in clearance of small α-synuclein aggregates by astrocytes associated with an increased astrocytic reactivity in the A53T transgenic mouse model. Key Points: The substantia nigra pars compacta contains a higher density of astrocytes than the ventral tegmental area or striatum, indicating a greater reliance on astrocytic function and a greater vulnerability to astrocyte dysfunction Small aggregates of α-synuclein were observed in wild-type midbrain and striatal astrocytes, indicating normal clearance of α-synuclein by these astrocytes Midbrain and striatal astrocytes from A53T transgenic astrocytes have more than double the number of astrocytes and more astrocytes containing α-synuclein aggregates which have a reactive morphological phenotype.
- Open Access
Dopamine and cortical iPSC-derived neurons with different Parkinsonian mutations show variation in lysosomal and mitochondrial dysfunction: implications for protein deposition versus selective cell loss
Background: Mutations causing Parkinson’s disease (PD) give diverse pathological phenotypes whose cellular correlates remain to be determined. For example, those with PRKN loss of function mutations have significantly earlier selective vulnerability of dopamine neurons, those with SNCA mutations have increased alpha-synuclein deposition, while those with LRRK2 mutations have additional deposition of tau. Yet all three mutation types are implicated in mitochondrial and/or lysosomal dysfunction. Direct comparison of cell models with these mutations would clarify the relative cellular dysfunctions associated with these different pathological phenotypes. Methods: An unbiased high-content imaging platform using orthogonal probes to assess both lysosomal and mitochondrial dysfunction, along with alpha-synuclein and tau protein deposition was established using induced pluripotent stem cell (iPSC) derived cortical and ventral midbrain neurons. Three mutation types, SNCA A53T, LRRK2 R1441G and PRKN loss of function (lof), were selected as exemplars of divergent PD pathological phenotypes and compared to each other, and to control iPSC from subjects without PD. Results: Different PD mutations caused cell type specific dysfunctions, likely to impact on both selective neuronal vulnerability and the pathologies observed in PD. Comparison of dopamine neurons identified that both lysosomal and mitochondrial dysfunction were predominant with PRKN lof mutations, whereas immunofluorescent staining revealed that SNCA A53T and LRRK2 R1441G mutations had increased tau deposition. In contrast, cortical neurons with SNCA and LRRK2 mutations both had mitochondrial and autophagy impairments without protein deposition, with LRRK2 cells additionally showing decreased glucocerebrosidase activity and increased alpha-synuclein phosphorylation. Conclusions: Lysosomal and mitochondrial dysfunction are predominant in dopamine neurons with PRKN lof mutations, and may drive the early selective loss of dopamine neurons in PRKN mutation carriers. More subtle cellular abnormalities in the SNCA A53T cell lines are likely to predispose to alpha-synuclein aggregation and tau protein deposition over time. The LRRK2 R1441G may also predispose to tau deposition, but despite substantial lysosomal dysfunction with increased alpha-synuclein phosphorylation, pathological alpha-synuclein accumulations were not observed. Understanding the mechanistic differences in how lysosomal and mitochondrial dysfunction impact on PD pathogenesis in different disease subtypes may be important for therapeutic development.
Open AccessDopamine and cortical iPSC-derived neurons with different Parkinsonian mutations show variation in lysosomal and mitochondrial dysfunction: implications for protein deposition versus selective cell loss
Background: Mutations causing Parkinson’s disease (PD) give diverse pathological phenotypes whose cellular correlates remain to be determined. For example, those with PRKN loss of function mutations have significantly earlier selective vulnerability of dopamine neurons, those with SNCA mutations have increased alpha-synuclein deposition, while those with LRRK2 mutations have additional deposition of tau. Yet all three mutation types are implicated in mitochondrial and/or lysosomal dysfunction. Direct comparison of cell models with these mutations would clarify the relative cellular dysfunctions associated with these different pathological phenotypes. Methods: An unbiased high-content imaging platform using orthogonal probes to assess both lysosomal and mitochondrial dysfunction, along with alpha-synuclein and tau protein deposition was established using induced pluripotent stem cell (iPSC) derived cortical and ventral midbrain neurons. Three mutation types, SNCA A53T, LRRK2 R1441G and PRKN loss of function (lof), were selected as exemplars of divergent PD pathological phenotypes and compared to each other, and to control iPSC from subjects without PD. Results: Different PD mutations caused cell type specific dysfunctions, likely to impact on both selective neuronal vulnerability and the pathologies observed in PD. Comparison of dopamine neurons identified that both lysosomal and mitochondrial dysfunction were predominant with PRKN lof mutations, whereas immunofluorescent staining revealed that SNCA A53T and LRRK2 R1441G mutations had increased tau deposition. In contrast, cortical neurons with SNCA and LRRK2 mutations both had mitochondrial and autophagy impairments without protein deposition, with LRRK2 cells additionally showing decreased glucocerebrosidase activity and increased alpha-synuclein phosphorylation. Conclusions: Lysosomal and mitochondrial dysfunction are predominant in dopamine neurons with PRKN lof mutations, and may drive the early selective loss of dopamine neurons in PRKN mutation carriers. More subtle cellular abnormalities in the SNCA A53T cell lines are likely to predispose to alpha-synuclein aggregation and tau protein deposition over time. The LRRK2 R1441G may also predispose to tau deposition, but despite substantial lysosomal dysfunction with increased alpha-synuclein phosphorylation, pathological alpha-synuclein accumulations were not observed. Understanding the mechanistic differences in how lysosomal and mitochondrial dysfunction impact on PD pathogenesis in different disease subtypes may be important for therapeutic development.
- Open Access
- 29 August 2014
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (8) , e102909
Systems-Based Analyses of Brain Regions Functionally Impacted in Parkinson's Disease Reveals Underlying Causal Mechanisms
Detailed analysis of disease-affected tissue provides insight into molecular mechanisms contributing to pathogenesis. Substantia nigra, striatum, and cortex are functionally connected with increasing degrees of alpha-synuclein pathology in Parkinson's disease. We undertook functional and causal pathway analysis of gene expression and proteomic alterations in these three regions, and the data revealed pathways that correlated with disease progression. In addition, microarray and RNAseq experiments revealed previously unidentified causal changes related to oligodendrocyte function and synaptic vesicle release, and these and other changes were reflected across all brain regions. Importantly, subsets of these changes were replicated in Parkinson's disease blood; suggesting peripheral tissue may provide important avenues for understanding and measuring disease status and progression. Proteomic assessment revealed alterations in mitochondria and vesicular transport proteins that preceded gene expression changes indicating defects in translation and/or protein turnover. Our combined approach of proteomics, RNAseq and microarray analyses provides a comprehensive view of the molecular changes that accompany functional loss and alpha-synuclein pathology in Parkinson's disease, and may be instrumental to understand, diagnose and follow Parkinson's disease progression.
- 29 August 2014
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (8) , e102909
Open AccessSystems-Based Analyses of Brain Regions Functionally Impacted in Parkinson's Disease Reveals Underlying Causal Mechanisms
Detailed analysis of disease-affected tissue provides insight into molecular mechanisms contributing to pathogenesis. Substantia nigra, striatum, and cortex are functionally connected with increasing degrees of alpha-synuclein pathology in Parkinson's disease. We undertook functional and causal pathway analysis of gene expression and proteomic alterations in these three regions, and the data revealed pathways that correlated with disease progression. In addition, microarray and RNAseq experiments revealed previously unidentified causal changes related to oligodendrocyte function and synaptic vesicle release, and these and other changes were reflected across all brain regions. Importantly, subsets of these changes were replicated in Parkinson's disease blood; suggesting peripheral tissue may provide important avenues for understanding and measuring disease status and progression. Proteomic assessment revealed alterations in mitochondria and vesicular transport proteins that preceded gene expression changes indicating defects in translation and/or protein turnover. Our combined approach of proteomics, RNAseq and microarray analyses provides a comprehensive view of the molecular changes that accompany functional loss and alpha-synuclein pathology in Parkinson's disease, and may be instrumental to understand, diagnose and follow Parkinson's disease progression.
- Open Access
- 14 February 2014
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (2) , e87133
Targeting the Intrinsically Disordered Structural Ensemble of α-Synuclein by Small Molecules as a Potential Therapeutic Strategy for Parkinson’s Disease
The misfolding of intrinsically disordered proteins such as α-synuclein, tau and the Aβ peptide has been associated with many highly debilitating neurodegenerative syndromes including Parkinson’s and Alzheimer’s diseases. Therapeutic targeting of the monomeric state of such intrinsically disordered proteins by small molecules has, however, been a major challenge because of their heterogeneous conformational properties. We show here that a combination of computational and experimental techniques has led to the identification of a drug-like phenyl-sulfonamide compound (ELN484228), that targets α-synuclein, a key protein in Parkinson’s disease. We found that this compound has substantial biological activity in cellular models of α-synuclein-mediated dysfunction, including rescue of α-synuclein-induced disruption of vesicle trafficking and dopaminergic neuronal loss and neurite retraction most likely by reducing the amount of α-synuclein targeted to sites of vesicle mobilization such as the synapse in neurons or the site of bead engulfment in microglial cells. These results indicate that targeting α-synuclein by small molecules represents a promising approach to the development of therapeutic treatments of Parkinson’s disease and related conditions.
- 14 February 2014
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (2) , e87133
Open AccessTargeting the Intrinsically Disordered Structural Ensemble of α-Synuclein by Small Molecules as a Potential Therapeutic Strategy for Parkinson’s Disease
The misfolding of intrinsically disordered proteins such as α-synuclein, tau and the Aβ peptide has been associated with many highly debilitating neurodegenerative syndromes including Parkinson’s and Alzheimer’s diseases. Therapeutic targeting of the monomeric state of such intrinsically disordered proteins by small molecules has, however, been a major challenge because of their heterogeneous conformational properties. We show here that a combination of computational and experimental techniques has led to the identification of a drug-like phenyl-sulfonamide compound (ELN484228), that targets α-synuclein, a key protein in Parkinson’s disease. We found that this compound has substantial biological activity in cellular models of α-synuclein-mediated dysfunction, including rescue of α-synuclein-induced disruption of vesicle trafficking and dopaminergic neuronal loss and neurite retraction most likely by reducing the amount of α-synuclein targeted to sites of vesicle mobilization such as the synapse in neurons or the site of bead engulfment in microglial cells. These results indicate that targeting α-synuclein by small molecules represents a promising approach to the development of therapeutic treatments of Parkinson’s disease and related conditions.
- Open Access
- 23 August 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (8) , e71634
Elevated Alpha-Synuclein Impairs Innate Immune Cell Function and Provides a Potential Peripheral Biomarker for Parkinson's Disease
Alpha-synuclein protein is strongly implicated in the pathogenesis Parkinson's disease. Increased expression of α-synuclein due to genetic multiplication or point mutations leads to early onset disease. While α-synuclein is known to modulate membrane vesicle dynamics, it is not clear if this activity is involved in the pathogenic process or if measurable physiological effects of α-synuclein over-expression or mutation exist in vivo. Macrophages and microglia isolated from BAC α-synuclein transgenic mice, which overexpress α-synuclein under regulation of its own promoter, express α-synuclein and exhibit impaired cytokine release and phagocytosis. These processes were affected in vivo as well, both in peritoneal macrophages and microglia in the CNS. Extending these findings to humans, we found similar results with monocytes and fibroblasts isolated from idiopathic or familial Parkinson's disease patients compared to age-matched controls. In summary, this paper provides 1) a new animal model to measure α-synuclein dysfunction; 2) a cellular system to measure synchronized mobilization of α-synuclein and its functional interactions; 3) observations regarding a potential role for innate immune cell function in the development and progression of Parkinson's disease and other human synucleinopathies; 4) putative peripheral biomarkers to study and track these processes in human subjects. While altered neuronal function is a primary issue in PD, the widespread consequence of abnormal α-synuclein expression in other cell types, including immune cells, could play an important role in the neurodegenerative progression of PD and other synucleinopathies. Moreover, increased α-synuclein and altered phagocytosis may provide a useful biomarker for human PD.
- 23 August 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (8) , e71634
Open AccessElevated Alpha-Synuclein Impairs Innate Immune Cell Function and Provides a Potential Peripheral Biomarker for Parkinson's Disease
Alpha-synuclein protein is strongly implicated in the pathogenesis Parkinson's disease. Increased expression of α-synuclein due to genetic multiplication or point mutations leads to early onset disease. While α-synuclein is known to modulate membrane vesicle dynamics, it is not clear if this activity is involved in the pathogenic process or if measurable physiological effects of α-synuclein over-expression or mutation exist in vivo. Macrophages and microglia isolated from BAC α-synuclein transgenic mice, which overexpress α-synuclein under regulation of its own promoter, express α-synuclein and exhibit impaired cytokine release and phagocytosis. These processes were affected in vivo as well, both in peritoneal macrophages and microglia in the CNS. Extending these findings to humans, we found similar results with monocytes and fibroblasts isolated from idiopathic or familial Parkinson's disease patients compared to age-matched controls. In summary, this paper provides 1) a new animal model to measure α-synuclein dysfunction; 2) a cellular system to measure synchronized mobilization of α-synuclein and its functional interactions; 3) observations regarding a potential role for innate immune cell function in the development and progression of Parkinson's disease and other human synucleinopathies; 4) putative peripheral biomarkers to study and track these processes in human subjects. While altered neuronal function is a primary issue in PD, the widespread consequence of abnormal α-synuclein expression in other cell types, including immune cells, could play an important role in the neurodegenerative progression of PD and other synucleinopathies. Moreover, increased α-synuclein and altered phagocytosis may provide a useful biomarker for human PD.
- Open Access
- 30 July 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (7)
Correction: Label Free Fragment Screening Using Surface Plasmon Resonance as a Tool for Fragment Finding – Analyzing Parkin, a Difficult CNS Target
- 30 July 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (7)
Open AccessCorrection: Label Free Fragment Screening Using Surface Plasmon Resonance as a Tool for Fragment Finding – Analyzing Parkin, a Difficult CNS Target